IOL Chemicals & Pharmaceuticals Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.8K Cr
The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26 despite current market challenges. Expect topline growth of around 10% to 12% considering current scenario (Abhay Raj Singh).
From IOL Chemicals & Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹170
Market Cap
₹4.8K Cr
P/E Ratio
32.8
How does IOL Chemicals & Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare IOL Chemicals & Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹53 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26 despite current market challenges.
- →Demand and pricing in pharma and chemical sectors are expected to improve starting FY26, aiding growth.
- →Chemical sector experts and company management expect recovery in chemical and API segments beginning Q2 onwards.
- →There is focus on increasing exports, especially to Europe and Latin America, targeting 40%-45% export share in the coming years.
- →Capacity utilization is aimed to increase from current ~75% towards 90% in the near term, enhancing volumes.
- →New product approvals and market expansions, including REACH certification and entry into European markets, are key growth drivers.
- →Ongoing efforts to onboard new clients in the US market are expected to yield benefits over 2-3 quarters.
- →New facility development on acquired land to expand chemical and API production is planned within 18-24 months.
📈 Profitability & Margins
- →Expect topline growth of around 10% to 12% considering current scenario (Abhay Raj Singh).
- →Anticipated recovery in chemical and API sectors starting Q2 FY26, leading to improved revenues (Abhay Raj Singh).
- →EBITDA margin expected to improve towards 13%-15% in the coming years (Rakesh Mahajan).
- →Operating profit margins targeted to reach double digits from Q1 or Q2 next fiscal, with easing pricing pressures (Abhay Raj Singh).
- →Capacity utilization improvements (targeting ~90% in 2-3 quarters) to support margin expansion (Pardeep Khanna, Rakesh Mahajan).
- →Increased exports and new market expansions, especially in Europe and Latin America, seen as growth drivers (Rakesh Mahajan, Pradeep Khanna).
- →Ongoing efforts to onboard new customers in US could add to revenue streams in 2-3 quarters (Rakesh Mahajan).
- →Overall optimistic outlook for FY26 and beyond, expecting better market conditions to reflect in earnings and share price.
🏗️ Capital Expenditure Plans
- →The company has made capital expenditures (CAPEX) of Rs. 54 crore in Q3 FY25, lower than Rs. 80 crore in Q3 FY24 and Rs. 83 crore in Q2 FY25.
- →Recent CAPEX includes starting acetic anhydride and other products, revamping the cogeneration plant, and environmental equipment including Effluent Treatment Plant (ETP).
- →A new land was acquired on Chandigarh-Bhatinda Highway for setting up new facilities with a mix of chemicals and API plants; specific products are being finalized.
- →Environmental approvals are in process, and the company expects to ramp up operations on the new land within 18 to 24 months.
- →The business model and product focus at the new facility aim to remain consistent with current operations.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or future fundraising plans through debt or equity.
- →No discussion or indication of new capital raising initiatives was found in the Q3 & 9M FY25 earnings conference call.
- →The focus of the management was on operational performance, capacity utilization, and margin improvement.
- →There was no reference to plans for issuing new shares or taking on new debt financing.
- →The company declared an interim dividend, indicating cash distribution to shareholders rather than raising capital.
- →Overall, the document does not reveal any intention for debt or equity fundraising in the near term.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were IOL Chemicals & Pharmaceuticals Ltd Q3 FY25 results?
The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26 despite current market challenges. Expect topline growth of around 10% to 12% considering current scenario (Abhay Raj Singh).
What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?
IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹4,797 Cr. Investors should review the full earnings analysis for detailed insights.
Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?
The company has made capital expenditures (CAPEX) of Rs.
Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.